AbbVie Inc. Retained Earnings
AbbVie Inc. (ABBV) had Retained Earnings of -$17.33 billion as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-03
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$17.33B.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$17.87B.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$15.49B.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$14.23B.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$17.33B 10-Q · filed 2026-08-03 |
| 2026-03-31 | -$17.87B 10-Q · filed 2026-05-08 |
| 2025-12-31 | -$15.49B 10-Q · filed 2026-08-03 |
| 2025-09-30 | -$14.23B 10-Q · filed 2025-11-04 |
| 2025-06-30 | -$11.50B 10-Q · filed 2025-08-04 |
| 2025-03-31 | -$9.53B 10-Q · filed 2025-05-09 |
| 2024-12-31 | -$7.90B 10-K · filed 2026-02-20 |
| 2024-09-30 | -$4.96B 10-Q · filed 2024-11-04 |
| 2024-06-30 | -$3.77B 10-Q · filed 2024-08-07 |
| 2024-03-31 | -$2.38B 10-Q · filed 2024-05-03 |
| 2023-12-31 | -$1.00B 10-K · filed 2025-02-14 |
| 2023-09-30 | $933.00M 10-Q · filed 2023-11-06 |
| 2023-06-30 | $1.79B 10-Q · filed 2023-08-07 |
| 2023-03-31 | $2.39B 10-Q · filed 2023-05-05 |
| 2022-12-31 | $4.78B 10-K · filed 2024-02-20 |
| 2022-09-30 | $4.95B 10-Q · filed 2022-11-04 |
| 2022-06-30 | $3.52B 10-Q · filed 2022-08-04 |
| 2022-03-31 | $5.10B 10-Q · filed 2022-05-06 |
| 2021-12-31 | $3.13B 10-K · filed 2023-02-17 |
| 2021-09-30 | $1.60B 10-Q · filed 2021-11-02 |
| 2021-06-30 | $740.00M 10-Q · filed 2021-08-02 |
| 2021-03-31 | $2.29B 10-Q · filed 2021-05-07 |
| 2020-12-31 | $1.05B 10-K · filed 2022-02-18 |
| 2020-09-30 | $3.33B 10-Q · filed 2020-11-04 |
| 2020-06-30 | $3.13B 10-Q · filed 2020-08-04 |
| 2020-03-31 | $5.97B 10-Q · filed 2020-05-08 |
| 2019-12-31 | $4.72B 10-K · filed 2021-02-19 |
| 2019-09-30 | $3.67B 10-Q · filed 2019-11-06 |
| 2019-06-30 | $3.38B 10-Q · filed 2019-08-05 |
| 2019-03-31 | $4.23B 10-Q · filed 2019-05-03 |
| 2018-12-31 | $3.37B 10-K · filed 2020-02-21 |
| 2018-09-30 | $6.79B 10-Q · filed 2018-11-07 |
| 2018-06-30 | $5.50B 10-Q · filed 2018-08-07 |
| 2018-03-31 | $4.98B 10-Q · filed 2018-05-04 |
| 2017-12-31 | $5.46B 10-K · filed 2019-02-27 |
| 2017-09-30 | $6.55B 10-Q · filed 2017-11-07 |
| 2017-06-30 | $5.95B 10-Q · filed 2017-08-07 |
| 2017-03-31 | $5.06B 10-Q · filed 2017-05-05 |
| 2016-12-31 | $4.38B 10-K · filed 2018-02-16 |
| 2016-09-30 | $4.01B 10-Q · filed 2016-11-07 |
| 2016-06-30 | $3.35B 10-Q · filed 2016-08-05 |
| 2016-03-31 | $2.67B 10-Q · filed 2016-05-06 |
| 2015-12-31 | $2.25B 10-K · filed 2017-02-17 |
| 2015-09-30 | $1.65B 10-Q · filed 2015-11-06 |
| 2015-06-30 | $1.26B 10-Q · filed 2015-08-07 |
| 2015-03-31 | $739.00M 10-Q · filed 2015-05-08 |
| 2014-12-31 | $535.00M 10-K · filed 2016-02-19 |
| 2014-09-30 | $2.13B 10-Q · filed 2014-11-07 |
| 2014-06-30 | $2.30B 10-Q · filed 2014-08-07 |
| 2014-03-31 | $1.87B 10-Q · filed 2014-05-09 |
| 2013-12-31 | $1.57B 10-K · filed 2015-02-20 |
| 2013-09-30 | $1.08B 10-Q · filed 2013-11-12 |
| 2013-06-30 | $758.00M 10-Q · filed 2013-08-09 |
| 2013-03-31 | $330.00M 10-Q · filed 2013-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |